Rhythm Pharmaceuticals (RYTM) Research & Development (2016 - 2026)

Rhythm Pharmaceuticals (RYTM) has 11 years of Research & Development data on file, last reported at $41.7 million in Q1 2026.

• On a quarterly basis, Research & Development rose 12.85% year-over-year to $41.7 million in Q1 2026; TTM through Mar 2026 was $172.1 million, a 17.66% increase from a year earlier, with the FY2025 full-year figure at $167.3 million, down 29.68% from the prior year.
• Research & Development for Q1 2026 stood at $41.7 million, down from $42.0 million in the prior quarter.
• Over the last five years, Research & Development for RYTM reached as high as $128.7 million in Q1 2024 and fell as low as $21.1 million in Q3 2022.
• Historically, Research & Development has averaged $40.6 million across 5 years, with a median of $37.0 million in 2025.
• Across the five-year window, Research & Development jumped 239.08% in 2024 and plunged 71.26% in 2025, its largest moves.
• Year by year, Research & Development stood at $23.5 million in 2022, then gained by 26.94% to $29.9 million in 2023, then soared by 37.72% to $41.2 million in 2024, then rose by 2.1% to $42.0 million in 2025, then retreated by 0.73% to $41.7 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $41.7 million in Q1 2026, $42.0 million in Q4 2025, and $46.0 million in Q3 2025.